News

Results of Scientific & Practical Olympiad "Mexidol®: 20 years in Clinical Practice"

Dear colleagues!

The IIIrd Scientific & Practical Olympiad "Mexidol^®: 20 years in clinical practice" was successfully completed!

The Olympiad became a traditional expected event, before the third Olympiad there were the first, which took place in 2005 - 2006, and the second one, 2010-2011.

The Olympiad was held under the aegis of the Russian Scientific Medical Society of Physicians (RSMSP).

The goal of the Olympiad was to summarize the experience of clinical use and research of Mexidol^® and to identify promising directions for using Mexidol^® in various areas of medicine, new directions for experimental, fundamental preclinical research on effect of oxidative stress on main pathophysiological processes in organism.

Members of Presidium of the Expert Council were: Academician of the Russian Academy of Sciences (RAS), President of RSMSP, Honored Scientist of the RF, Doctor of Medical Sciences, Professor Anatoly Ivanovich Martynov; Academician of the RAS, Chairman of the All-Russian Society of Neurologists, Head of the Department of Neurology & Neurosurgery, RNRMU named after N.I. Pirogov, Professor Evgeny Ivanovich Gusev; General Secretary of RSMSP, Doctor of Medical Sciences, Professor Andrei Aleksandrovich Spassky; Corresponding Member of RAS, Director of the State Research Center for Preventive Medicine, Chief Therapeutist of Central Federal District, Doctor of Medical Sciences, Professor Sergey Anatolievich Boytsov; Vice-President of RSMSP, Head of the Department of Internal Diseases & General Physiotherapy of the Department of Pediatrics of RNRMU named after N.I. Pirogov, Honored Doctor of the RF, Corresponding Member of RAS, Doctor of Medical Sciences, Professor Grigory Pavlovich Arutyunov. Leading neurologists and well-known specialists of other specialties were in the Expert Council: Director of Research Institute of Cerebrovascular Pathology & Stroke of RNRMU named after N.I. Pirogov, Doctor of Medical Sciences, Professor Lyudmila Vitalyevna Stakhovskaya; Chief Specialist on Medical Rehabilitation of the Ministry of Healthcare of the RF, Doctor of Medical Sciences, Professor Galina Evgenyevna Ivanova; Doctor of Medical Sciences, Professor Anatoly Ivanovich Fedin; Chief Ophthalmologist of the Medical Center of Administrative Directorate of the President of the RF, Doctor of Medical Sciences, Professor Evgeny Alekseevich Egorov and many others.

The participants of the Olympiad represented various scientific and medical institutions from different regions of our country.

The Olympiad covered the most important medical directions, such as therapy, neurology, cardiology, psychiatry, ophthalmology and many others.

On November 23, 2017, in Moscow, within the framework of the finished XIIth National Congress of Physicians, results of the Scientific & Practical Olympiad were summarized. The Expert Council identified winners in four nominations:

* Nomination "The Best Scientific Research on the Preparation Mexidol^®"

* Nomination "The Best Scientific or Scientific & Practical Work of Young Scientists, Dedicated to Research and Administration of the Preparation of Mexidol^®"

Also, the Expert Council marked scientific research of Abramova Valeriya Nikolaevna, Tver.

* Nomination "The Best Scientific & Practical Work, Summarizing Clinical Experience of Administration of the Preparation of Mexidol^®"

The Expert Council marked scientific works of Mikaelyan Marina Filippovna, Pyatigorsk, and Chepukhina Larisa Alexandrovna, Tolyatti.

* Nomination "The Best Experimental, Fundamental Preclinical Research"

The Expert Council marked scientific research of Kurilov Igor Nikolaevich, Chelyabinsk.

Awards and diplomas of awardees and winners of the Olympiad were presented by General Secretary of RSMSP, Doctor of Medical Sciences, Professor Andrei Aleksandrovich Spassky; Vice-President of RSMSP, Head of the Department of Internal Diseases & General Physiotherapy of the Department of Pediatrics of RNRMU named after N.I. Pirogov, Honored Doctor of the RF, Corresponding Member of RAS, Doctor of Medical Sciences, Professor Grigory Pavlovich Arutyunov and Special Representative of RSMSP in Siberian & Far Eastern Federal Districts, Academician of RAS, Doctor of Medical Sciences, Professor Voevoda Mikhail Ivanovich.

Within the framework of the Symposium, reports were made by: Andrei Aleksandrovich Spassky, Doctor of Medical Sciences, Professor - "Olympiad" Mexidol^® - 20 years in clinical practice: Yesterday, Today, Tomorrow", Shchulkin Alexey Vladimirovich, Candidate of Medical Sciences, Winner of the IInd Olympiad 2010-2011 - Mexidol^®: Pharmacological & Clinical Effects, Implementation in Clinical Practice", Fedin Anatoly Ivanovich, Doctor of Medical Sciences, Professor - "The Role of Ischemia & Hypoxia in Development of Neurological Diseases". Winners of the IIIrd Scientific & Practical Olympiad presented reports on results of their work.

The works will be published in leading medical periodicals.

The IXth International Congress "Neurorehabilitation-2017"

On June 1-2, the IXth International Congress "Neurorehabilitation-2017" was held in Moscow.

The event was held with support of the Ministry of Healthcare of Russia, Russian Association of Rehabilitation and the National Stroke Association (NSA). Within the framework of the Congress, an exhibition event was also held, in which LLC "Vectorpharm", the distributor of preparations of LLC "Scientific Production Company "PHARMASOFT" (LLC "SPC "PHARMASOFT"), took part.

The scientific program of the Congress was devoted to rehabilitation in vascular diseases, injuries and tumors of central nervous system. During the Congress, an annual session for managers and employees of regional vascular centers and primary vascular units was held, where basic principles of organization of rehabilitation activities for patients with cerebral stroke in settings of vascular units and peculiarities of training personnel for work in vascular units were examined, criteria for efficacy of rehabilitation were discussed and clinical protocols were approved.

Symposium "Peculiarities of Rehabilitation of an Elderly Patient with Cerebrovascular Disease" aroused great interest of the Congress participants. The report "Rehabilitation Potential in Elderly Patients with CVD (cerebrovascular disease)" was presented by Doctor of Medical Sciences, Professor Fedin Anatoly Ivanovich. The speaker focused on ways to improve compliance, and, consequently, the effectiveness of therapy, and emphasized on the need to prescribe to such patients drugs with a multimodal effect, a prominent representative of which is antioxidant and antihypoxant Mexidol^®. Within the framework of the Symposium, the results of randomized, double-blind, multicenter, placebo-controlled parallel-group study of efficacy and safety of Mexidol^® in treatment of ischemic stroke (EPICA) were presented by Doctor of Medical Sciences, Professor Stakhovskaya Lyudmila Vitalievna.

151 patients (62 men and 89 women) were enrolled to the study, 150 patients (62 men and 88 women) aged 40 to 79 years were randomized. The patients were randomly assigned to 2 groups: patients of the 1st group were treated with Mexidol, 500 mg/day, by intravenously drop infusion, for 10 days, followed by taking 1 tablet (125 mg) 3 times a day for 8 weeks, patients of the 2nd group received a placebo by the same regimen. The duration of participation in the study was 67 to 71 days. At the end of the therapy, the mean score by modified Rankin Scale (mRS) was lower in the 1st group than in the 2nd one (p = 0.04). Dynamics of decrease in average score by mRS (1-5th visits) was more evident in the 1st group (p = 0.023). The proportion of patients, who achieved a recovery, corresponding to 0-2 points by mRS (5th visit), was significantly higher in the 1st group (p = 0.039). During the therapy with Mexidol, significantly more evident improvement in comparison with placebo was observed, as measured by modified Rankin Scale. At the end of the therapy, the level of life activities was significantly higher in the Mexidol therapy group. When tested by Stroke Scale of National Institute of Health at the 5th visit, the mean value was lower in the 1st group (p = 0.035), at the end of the therapy, the neurologic impairment was significantly lower in Mexidol therapy group. The decrease in score by Stroke Scale of National Institute of Health at the end of the course of the therapy relative to baseline in patients with diabetes mellitus was more evident in the 1st group (p = 0.038). In the 1st group, in general population of patients and subpopulation of patients with diabetes mellitus, the dynamics of improving quality of life was more evident and was observed since the 2nd visit. The proportion of patients with no problem with mobility in space was significantly higher in the 1st group (p = 0.022). The majority of patients in Mexidol therapy group noted that they did not have any problems with movement, self-care, everyday activities, did not experience pain and discomfort, anxiety and depression. There were no significant differences in incidence of adverse events in patients of both groups. The results of the study show that Mexidol^® in the regimen of sequential therapy has a favorable profile of tolerability and safety. It is recommended to include Mexidol^® into therapy of patients in acute and early recovery periods of IS (Ischaemic Stroke).

The peculiarities of pharmacological support for rehabilitation of elderly patients were reported by Doctor of Medical Sciences, Professor Ushkalova Elena Andreevna. Mexidol^® was presented as in detail examined preparation with a high safety profile.

Participation in the event allowed doctors to obtain additional information on new technologies for recovery and maintenance of functions of patients with cerebral stroke at various stages of rehabilitation treatment.

At the stand of LLC "Vectorpharm", doctors could take a close look at informational materials on problems of neurorehabilitation in modern medicine in the context of effectiveness of anti-ischemic preparation Mexidol^®, which has antioxidant, antihypoxic, and membranotropic effects.

The XIth National Congress of Physicians

On November 23-25, the XIth National Congress of Physicians was held in Moscow - the main annual event of the Russian Scientific Medical Society of Therapists (RSMST).

Within the framework of the congress, an exhibition event was also held, in which LLC "SPC "PHARMASOFT" took part.

The scientific program of the Congress was devoted to a wide range of issues of diagnosis, prevention and treatment of internal diseases.

On November 23, 2016, Master class "What the therapist needs to know about the rehabilitation of patient after a vascular catastrophe" was held in the framework of the Сongress, the presenter was Kovalchuk Vitaly Vladimirovich, Doctor of Medical Sciences, Professor, Chairman of the Society of Rehabilitation Professionals of St. Petersburg, Head of the Center for Medical Rehabilitation. The master class aroused great interest of specialists, involved in rehabilitation of patients after stroke. Mexidol^® was presented as an integral pharmacological support for rehabilitation process, an antioxidant and an antihypoxant that affects on syndromes that complicate rehabilitation - syndrome of neglect and repulsion.

On November 24, 2016, in the framework of the Congress, the Symposium "Comorbidity in the Practice of the Therapist: Heart, Brain, Blood Vessels" was held. The chairman of the Symposium was Doctor of Medical Sciences, Professor Andrei Alexandrovich Spassky, General Secretary of the RSMSP. Mechanism of development and realization of vascular pathology and general principles of management of such patients were discussed at the Symposium, Mexidol^® was presented as an original domestic antioxidant and antihypoxant, effective in therapy of ischemia of any genesis. According to Co-chairman of the Symposium, Academician of the RAS Voevoda Mikhail Ivanovich, Mexidol^® is an example that, in Russia, high-quality preparations can be created and clinical research providing suitable evidential base can be conducted at the adequate level. The symposium aroused great interest of participants of the XIth National Congress of Physicians, engaged in vascular pathology.

At the stand of LLC "SPC "PHARMASOFT", doctors could take a close look at informational materials on problems of therapy in modern medicine in the context of effectiveness of anti-ischemic preparation Mexidol^®, which has antioxidant and antihypoxant effects.

Within the framework of the congress, an exhibition event was also held, in which LLC "SPC "PHARMASOFT" took part.

Mexidol® is a reference (original) preparation of ethylmethylhydroxypyridine succinate.

The 20th anniversary of administration of Mexidol^® in clinical practice is in 2016. Mexidol^® is the first preparation of ethylmethylhydroxypyridine succinate, included in the Order of the Ministry of Healthcare of the RF of December 31, 1996, No. 432 "On Permission for Medical Use".

In accordance with Federal Law No. 61-FZ of April 12, 2010 "On Drug Circulation", the preparation "Mexidol" (film-coated tablets, solution for intravenous and intramuscular injections) was recognized by FSBI (Federal State Budgetary Institution) "Scientific Center for Expertise of Medical Products" ("SCEMP") of the Ministry of Healthcare of Russia as referent (i.e. original) preparation of ethylmethylhydroxypyridine succinate.

Mexidol^® was synthesized in the early 1980s at State Institution Research Institute of Pharmacology of the RAMS (Russian Academy of Medical Sciences) under the supervision of Academician of RAMS A.V. Valdman by pharmacologists L.D. Smirnov and V.I. Kuzmin. In 2003, for development and introduction of Mexidol^® into clinical practice, a group of specialists was awarded by the RF Government Prize "For Creation and Introduction into Clinical Practice of Antioxidant Drugs for Treatment & Prevention of Cerebrovascular Diseases" (RF Government Decree No. 112 of February 18, 2003 "On Awarding Prizes from Government of the Russian Federation in 2002 in Science & Technology"). Based on confirmed data on clinical effectiveness, since 2006, Mexidol^® (GN ethylmethylhydroxypyridine succinate) is in the List of Vital & Essential Drugs (LVED). Mexidol^® (GN ethylmethylhydroxypyridine succinate) is included in bag of emergency medical care, and in 39 the most important standards of care, among them the Standard for specialized care in brain infarction (ischemic stroke), including prehospital phase, the Standard of Specialized Medical Care in disorders of intervertebral disc and other parts of spine with radiculopathy and other most current standards, used in neurology, narcology, psychiatry, ophthalmology, etc.

In 2014, Mexidol^® received the Russian Pharma Award in nomination "The drug of Choice in Treatment of Ischemic Disorders, Caused by Cerebral Vasospasm." Over the years, clinical use of Mexidol^® has been recognized by both medical community and patients, recovering the life energy after vascular catastrophes.

The 17th International Conference "Oxidative Stress Reduction, Redox Homeostasis & Antioxidants".

On June 14, within the framework of the 17th International Conference "Oxidative Stress Reduction, Redox Homeostasis & Antioxidants", which was held at the Pasteur Institute in Paris, the results of the study of the effectiveness of Mexidol on the reduction of degenerative processes in the brain in patients with multiple sclerosis were presented. The report was made by Doctor of Medical Sciences Prakhova Lidiya Nikolaevna (Institute of the Human Brain named after N.P. Bekhtereva of the RAS, St. Petersburg). The conference was attended by several hundred representatives from 45 countries, including European countries, the United States, China, Japan, Russia and others. The research results were published in the collection of the conference abstracts.

The IIIrd National Congress "EMERGENCY CONDITIONS IN NEUROLOGY"

In Moscow, on December 3, the IIIrd National Congress "EMERGENCY CONDITIONS IN NEUROLOGY" will be held.

The event is organized for all professionals, involved in first medical aid and emergency care, and acute disorders of cerebral circulation.

Prehospital stage is the first link in the system of medical care for patients with acute disorders of cerebral circulation. Effective operation of emergency medical service mainly determines the outcome of disease in patients with urgent vascular pathology of nervous system and contributes to continuity of patient management within multidisciplinary approach.

Continuity of management of patients with ACD & CCT, ways to improve results of therapy and increase proportion of patients with good functional outcome will be discussed at the Symposium "Continuity of medical care in urgent conditions in neurology", which will be held within the framework of the IIIrd National Congress "Urgent Conditions in Neurology".

Chairman of the Symposium - Doctor of Medical Sciences, Professor, Head of the Department of Neurology of the FAPE of RNRMU named after N.I. Pirogov Fedin Anatoly Ivanovich.

Program of the Symposium:

- Continuity of medical care in case of stroke. Fedin Anatoly Ivanovich.

- Management of patients with CCT at various stages of medical care. Interdisciplinary cooperation. Radushkevich Vladimir Leonidovich, Doctor of Medical Sciences, Professor, Head of the Emergency Medical Aid Department of the Institute of Further Professional Education (IFPE) of Voronezh State Medical University named after N.N. Burdenko (VSMU) (Voronezh)

- Laws and regulations of medical care in urgent conditions in neurology. Yanishevsky Stanislav Nikolaevich, Doctor of Medical Sciences, Associate Professor of the Department of Nervous Diseases of Military Medical Academy named after Kirov (Saint Petersburg).

Small Hall of the Mayor's office of the Government, Moscow, Novy Arbat str., 36

Time of the Meeting: December 03, 2015; from 3:00 pm to 5:00 pm.

The First International (for Russian speakers) Neurological School in Sudak "Innovations in Clinical Neurology"

On April 23-26, in Sudak, the First International (for Russian speakers) Neurological School "Innovations in Clinical Neurology" will be held under the chairmanship of Skvortsova Veronika Igorevna - Corresponding Member of RAS, Minister of Healthcare of the Russian Federation Gusev Evgeny Ivanovich - Academician of RAS, Chairman of the Management Board of All-Russian Society of Neurologists, Chief External Expert-Neurologist of the Ministry of Healthcare of the Russian Federation Mogilevsky Alexander Alekseevich - Minister of Healthcare of the Republic of Crimea

The School will be devoted to fundamental issues of theoretical and clinical neurology, the relevance of problems, issues of epidemiology and pathogenesis, classifications, algorithms of diagnostics and therapeutic complexes with comparison of the effectiveness of various drugs (original and generics), the sequence of their introduction will be reported.

Program of the event includes reports of leading specialists:

- Professor Fedin Anatoly Ivanovich (Moscow)

"Severe stroke. Pathogenesis, Diagnosis, Intensive Care"

- Professor Novikova Lilia Bareevna (Ufa)

"Modern Model of Recovery Management for Patients, Who Have Suffered a Stroke, in the Republic of Bashkortostan"

The Company "Vectorpharm" took part in the KOKStroke Education Program in Moscow

On January 21-22, 2015, the Educational Program of the Clinical & Educational Complex "Stroke" for specialists of multidisciplinary teams of Regional Vascular Centers (RVCs), Primary Vascular Departments (PVDs) and outpatient-polyclinic specialists was held in Moscow, based on State Budgetary Institution "Hospital for Veterans of Wars No. 3". The Moscow City Health Department, Hospital for Veterans of Wars No. 3, All-Russian Public Organization for Promotion of Medical Rehabilitation "Union of Rehabilitologists of Russia" and LLC "International Innovation Center for Rehabilitation & Kinesitherapy" took part in organization and implementation of the program. Multidisciplinary program of the event included issues, related to diagnosis, treatment and rehabilitation of patients with cerebral stroke. At the same time, the issues, raised at the event, on daily work of various specialists in vascular departments, were followed up additionally at practical seminars and master classes.

The event brought together about 200 specialists and took place with the participation of leading experts in this area from different regions of Russia: Chief Specialist of the Ministry of Healthcare of the RF on Medical Rehabilitation, Chairman of All-Russian Public Organization for the Promotion of Medical Rehabilitation "Union of Rehabilitologists of Russia" Professor, Doctor of Medical Sciences Ivanova Galina Evgenievna, Director of Research Institute of Cerebrovascular Pathology & Stroke (RI CVPS) of RNRMU named after N.I. Pirogov Professor, Doctor of Medical Sciences Stakhovskaya Lyudmila Vitalievna; Chief Specialist on Medical Rehabilitation of the Northwestern FD (Federal District) of the RF Professor, Doctor of Medical Sciences Melnikova Elena Valentinovna (the First St. Petersburg Medical University named after I.P. Pavlov), Chief Specialist of Ministry of Healthcare of the RF on Medical Rehabilitation of Ural Federal District of the RF, Chief Neurologist of Yekaterinburg, Director of Autonomous Noncommercial Organization "Clinical Institute of Brain", Professor of the Department of Nervous Diseases & Neurosurgery of Ural State Medical University, Doctor of Medical Sciences Belkin Andrey Avgustovich and representatives of other leading tertiary educational institutions and research institutions of Russia

Mexidol was presented as an antioxidant and antihypoxicant with a wide range of clinical effects, a pathogenetic component of therapy for acute cerebrovascular disorders. Real dosages of Mexidol in stroke therapy and need to prescribe Mexidol in stroke according to Standard for medical care in a cerebral infarction No. 1740n dated December 29, 2012 were disclosed.